Drugs / [177Lu]Lu-SN201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06184035 | Dec 2023 → Dec 2027 expected | metastatic malignant neoplasm, refractory malignant neoplasm | Spago Nanomedical AB | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-SN201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06184035 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT06184035 ↗ |